# A Phase II Study of SKB571 in Patients With Lung Cancer

Source: https://onco.cc/trials/nct07230405/  
OnCo record `nct07230405` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SKB571 for injection in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

A Phase II Study of SKB571 in Patients With Lung Cancer is a phase 2 interventional study registered as NCT07230405 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 295 participants planned, started 2026-01-19 and due to reach its primary completion in 2028-01-19. Interventions recorded: SKB571 for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07230405
- Phase: 2
- Setting: A Phase II Study to Evaluate the Safety and Efficacy of SKB571 in Patients With Advanced Non-small Cell Lung Cancer
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 295

## Sources

- ClinicalTrials.gov NCT07230405: https://clinicaltrials.gov/study/NCT07230405

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07230405.json